The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
EHA 2024 – Syndax sets up another menin inhibitor battle
Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
Kura leaves some combo questions unanswered
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Interview – Kura’s combo test nears
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
